ADXN Stock Overview
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Addex Therapeutics Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 9.95 |
| 52 Week High | CHF 27.90 |
| 52 Week Low | CHF 5.00 |
| Beta | 1.98 |
| 11 Month Change | 29.90% |
| 3 Month Change | 21.87% |
| 1 Year Change | 44.21% |
| 33 Year Change | -94.53% |
| 5 Year Change | n/a |
| Change since IPO | -96.57% |
Recent News & Updates
Recent updates
Addex, Indivior expand team up to develop therapies for substance use disorders
Aug 15Addex stock falls 11% amid $4.2M equity financing with Armistice
Jul 22Addex Therapeutics CEO Tim Dyer - Emerging Drugs For Central Nervous System (Video)
Oct 21Addex, Janssen initiate Phase 2 study of ADX71149 for epilepsy
Jun 07Addex Therapeutics reports Q1 results
May 05Addex drops 23% after pricing share offering
Jan 07Addex Therapeutics files to sell $10M of ADS
Dec 14Addex Therapeutics reports Q3 results
Nov 03Shareholder Returns
| ADXN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.8% | -3.8% | 1.8% |
| 1Y | 44.2% | 16.5% | 31.9% |
Return vs Industry: ADXN exceeded the US Biotechs industry which returned 18.7% over the past year.
Return vs Market: ADXN exceeded the US Market which returned 32.8% over the past year.
Price Volatility
| ADXN volatility | |
|---|---|
| ADXN Average Weekly Movement | 17.3% |
| Biotechs Industry Average Movement | 10.2% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ADXN's share price has been volatile over the past 3 months.
Volatility Over Time: ADXN's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 23 | Tim Dyer | www.addextherapeutics.com |
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson’s disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.
Addex Therapeutics Ltd Fundamentals Summary
| ADXN fundamental statistics | |
|---|---|
| Market cap | US$8.60m |
| Earnings (TTM) | -US$12.84m |
| Revenue (TTM) | US$1.62m |
5.3x
P/S Ratio-0.7x
P/E RatioIs ADXN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ADXN income statement (TTM) | |
|---|---|
| Revenue | CHF 1.38m |
| Cost of Revenue | CHF 6.93m |
| Gross Profit | -CHF 5.55m |
| Other Expenses | CHF 5.38m |
| Earnings | -CHF 10.92m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Sep 30, 2024
| Earnings per share (EPS) | -0.11 |
| Gross Margin | -401.85% |
| Net Profit Margin | -791.44% |
| Debt/Equity Ratio | 0% |
How did ADXN perform over the long term?
See historical performance and comparison